Similarly, while the MEK inhibitor binimetinib is part of NCCN recommendations for metastatic melanoma patients with Nras mutations, there is also no data reported to date about single-agent MEK inhibitors in MBM patients. Here, NRAS is linked to metastatic melanoma.